Improved global function and activities of daily living in patients with AD: a placebo-controlled clinical study with the neurotrophic agent Cerebrolysin®

  • D. F. Muresanu
  • M. Rainer
  • H. Moessler
Part of the Journal of Neural Transmission. Supplementa book series (NEURAL SUPPL, volume 62)


Background: Cerebrolysin® (Cere) is a peptidergic, neurotrophicdrug which has been shown to improve cognitive performance and global function of Alzheimer’s disease (AD) patients in earlier trials. In this study, we have attempted to replicate this findings with particular emphasis on functional improvement of the patients.

Patients and methods: Patients received infusions of 30ml Cere or placebo five days/week for six consecutive weeks. Patients had to have a diagnosis of AD and a MMSE score of 14–25 inclusive. Effects on cognition, global function, and activities of daily living were evaluated 3,6 and 18 weeks after the beginning of the infusions.

Results: Significant improvement of cognitive function, clinical global impression and activities of daily living were seen after the end of the therapy. The effects were most pronounced in the DAD score, a measure for the capability to perform activities of daily living. Interestingly, and in line with the findings of earlier studies, the treatment effect of Cere was maintained after cessation of treatment up to the week 18 assessment.

Conclusion: The data confirm the findings of earlier trials and clearly demonstrates that Cere leads to functional improvement of patients with AD. The sustained treatment effect of Cere after withdrawal has been confirmed.


Global Function MMSE Score Nootropic Drug Antidementia Drug Cere Treatment 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Akai F, Hiruma S, Sato T, etal (1992) Neurotrophic factor-like effect of FPF1070 on septal cholinergic neurons after transections of fimbria-fornix in the rat brain. Histol Histopathol 7: 213–221PubMedGoogle Scholar
  2. Bae C-Y, Cho C-Y, Cho K, Oh BH, Choi KG, Lee HS, Jung SP, Kim DH, Lee S, Choi G-D, Cho H, Lee H (2000) A double-blind, placebo-controlled, multicenter study of Cerebrolysin for Alzheimer’s disease. JAGS 48: 1566–1571Google Scholar
  3. Francis-Turner L, Valouskova V (1996) Nerve growth factor and nootropic drug Cerebrolysin but not fibroblast growth factor can reduce spatial memory impairment elicited by fimbria-fornix transection: short-term study. Neurosci Lett 202: 1–4CrossRefGoogle Scholar
  4. Folstein MF, Folstein SE, McHugh PR (1975) “Mini-Mental State”. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 12: 189–198PubMedCrossRefGoogle Scholar
  5. Gelinas I, Gauthier L, McIntyre M, Gauthier S (1999) Development of a functional measure for persons with Alzheimer’s disease: the disability assessment of dementia. AJOT 53: 471–481PubMedGoogle Scholar
  6. Gauthier S (1999) Acetylcholinesterase inhibitors in the treatment of Alzheimer’s disease. Exp Opin Exp Drugs 8: 1511–1520CrossRefGoogle Scholar
  7. Gray J, Gauthier S (1999) Stabilization approaches to Alzheimer’s disease. In: Gauthier S (ed) Clinical diagnosis and management of Alzheimer’s disease, 2nd ed. Martin Dunitz, London, p 269Google Scholar
  8. Gschanes A, Valouskova V, Windisch M (1997) Ameliorative influence of a nootropic drug on motor activity of rats after bilateral carotid artery occlusion. J Neural Transm 104: 1319–1327PubMedCrossRefGoogle Scholar
  9. Guy W (1976) ECDEU Assessment for psychopharmacology, rev edn. National Institute of Mental Health, Rockville, MDGoogle Scholar
  10. Masliah E, Armasolo F, Veinbergs I, Mallory M, Samuel W (1999) Cerebrolysin amelio-rates performance deficits, and neuronal damage in apolipoprotein E-deficient mice. Pharmacol Biochem Behav 62(2): 239–245PubMedCrossRefGoogle Scholar
  11. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM (1984) Clinical diagnosis of Alzheimer’s disease: report of the NINCDS-ADRDA Work Group under the auspices of the Department of Health and Human Services Task Force on Alzheimer’s Disease. Neurology 34: 11–39CrossRefGoogle Scholar
  12. Mohs RC, Knopman D, Petersen RC, Ferris SH, Ernesto C, Grundman M, Sano M, Bieliauskas L, Clark C, Thal LJ (1997) Development of cognitive instruments for use in clinical trials of antidementia drugs: additions to the Alzheimer’s disease assess-ment scale that broaden its scope. Alzheimer Dis Assoc Disord 11[Suppl 2]: S13–S21PubMedCrossRefGoogle Scholar
  13. Panisset M, Gauthier S, Moessler H, et al (2002) Cerebrolysin in Alzheimer’s disease: a randomized, double-blind, placebo-controlled trial with a neurotrophic agent. J Neural Transm 109: 1089–1104PubMedCrossRefGoogle Scholar
  14. Reinprecht I, Gschanes A, Windisch M, Fachbach G (1999) Two peptidergic drugs increase the synaptophysin immunoreactivity in brains of 24-month-old-rats. Histochem J 31: 395–401PubMedCrossRefGoogle Scholar
  15. Rockenstein E, Mallory M, Mante M, Sagara Y, Windisch M, Moessler H, Masliah E (2000) Effects of Cerebrolysin in human APP transgenic animal models of Alzheimer’s disease. Neurobiol Aging 21: 168CrossRefGoogle Scholar
  16. Rosen WG, Mohs RC, Davis KL (1984) A new rating scale for Alzheimer’sdisease.Am J Psychiatry 141: 1356–1364Google Scholar
  17. Ruether E, Ritter R, Apecechea M, Freytag S, Windisch M (1994) Efficacy of the peptidergic nootropic drug Cerebrolysin in patients with senile dementia of the Alzheimer type (SDAT). Pharmacopsychiatry 27(1): 32–40CrossRefGoogle Scholar
  18. Ruether E, Ritter R, Apecechea M, Freytag S, Gmeinbauer R, Windisch M (2000) Sustained improvements in patients with dementia of Alzheimer’s type (DAT) 6 months after termination of Cerebrolysin therapy. J Neural Transm 107: 815–829CrossRefGoogle Scholar
  19. Ruether E, Husmann R, Kinzler E, et al (2001) A 28 week, double-blind, placebo-controlled study with Cerebrolysin in patients with mild to moderate Alzheimer’s disease. Int Clin Pharmacol 16: 253–263Google Scholar
  20. Satou T, Imano M, Akai F, Hashimoto S, Hoh T, Fujimoto M (1993) Morphological observation of effects of Cerebrolysin on cultured neuronal cells. Adv Biosci 87: 195–196Google Scholar
  21. Tatebayashi Y, Lee MR, Iqbal K, Grundke-Iqbal I (2000) The peptidergic antidementia drug Cerebrolysin increases neurogenesis in the adult rat dentate gyrus and improves spatial learning and memory. Neurobiol Aging 21: S42CrossRefGoogle Scholar
  22. Valouskova V, Francis-Turner L (1998) Can Cerebrolysin influence chronic deterioration of spatial learning and memory? J Neural Transm 52[Suppl]: 343–349CrossRefGoogle Scholar

Copyright information

© Springer-Verlag Wien 2002

Authors and Affiliations

  • D. F. Muresanu
    • 1
  • M. Rainer
    • 2
  • H. Moessler
    • 3
  1. 1.Neurology DepartmentUniversity of Cluj-NapocaCluj-NapocaRomania
  2. 2.Psychiatry DepartmentHospital SMZ-OstVienna
  3. 3.EBEWE Pharmaceuticals Ltd.UnterachAustria

Personalised recommendations